Well, it is possible TURQUOISE-1 was intended for null responder cirrhotic patients GT1a/1b. Other than that, I don't see why would they want to run two similar trials for naive cirrhotic patients as TURQUOISE-2. Plus, if your reason were correct, there would be no reason for them not to separate GT1a/1b into different arms in TURQUOISE-2.
Market Data 
Markets 
AI
